AIM: To assess the sexuality and quality of life (QoL) of women with gynaecological malignancies after multimodal therapy. MATERIALS AND METHODS: This is a prospective analysis of the sexual status among women after treatment for gynaecological malignancies. Validated questionnaires-female sexual function index (FSFI-d), a semi-structured questionnaire and the quality of life score SF12, were applied. RESULTS: Overall, 55 patients (median age=61, range=22-74 years) were enrolled. The cancer diagnoses were 54% ovarian, 26% breast, 13% cervical, 6% vulvar and 2% endometrial cancer. Twenty patients (55.6%) claimed experiencing changes in their sexuality after cancer treatment. The main reasons for this impairment were distorsion of their self image (45%; n=9), dry vaginal mucosa (25%; n=5), fear of physical harm (20%; n=4) and pain during sexual intercourse (20%; n=4). Forty percent of the patients gave no information about their sexuality after cancer therapy. Patients with cervical, endometrial or vulvar cancer had significantly higher changes in their sexuality compared to patients with ovarian cancer even after adjusting for age, recurrence rate and partnership status. The evaluation of SF12 revealed significantly higher psychological functional scores with increasing age. Patients who reported changes of their sexuality were also shown to have a lower overall SF12 score. CONCLUSION: Evaluation of sexuality and self image perception after cancer treatment is an unmet need and needs to be addressed in women with gynaecological malignancies. Further studies are warranted to assess the influence of the various types of cancer therapies in regard to their effect on sexuality and quality of life.
AIM: To assess the sexuality and quality of life (QoL) of women with gynaecological malignancies after multimodal therapy. MATERIALS AND METHODS: This is a prospective analysis of the sexual status among women after treatment for gynaecological malignancies. Validated questionnaires-female sexual function index (FSFI-d), a semi-structured questionnaire and the quality of life score SF12, were applied. RESULTS: Overall, 55 patients (median age=61, range=22-74 years) were enrolled. The cancer diagnoses were 54% ovarian, 26% breast, 13% cervical, 6% vulvar and 2% endometrial cancer. Twenty patients (55.6%) claimed experiencing changes in their sexuality after cancer treatment. The main reasons for this impairment were distorsion of their self image (45%; n=9), dry vaginal mucosa (25%; n=5), fear of physical harm (20%; n=4) and pain during sexual intercourse (20%; n=4). Forty percent of the patients gave no information about their sexuality after cancer therapy. Patients with cervical, endometrial or vulvar cancer had significantly higher changes in their sexuality compared to patients with ovarian cancer even after adjusting for age, recurrence rate and partnership status. The evaluation of SF12 revealed significantly higher psychological functional scores with increasing age. Patients who reported changes of their sexuality were also shown to have a lower overall SF12 score. CONCLUSION: Evaluation of sexuality and self image perception after cancer treatment is an unmet need and needs to be addressed in women with gynaecological malignancies. Further studies are warranted to assess the influence of the various types of cancer therapies in regard to their effect on sexuality and quality of life.
Authors: Iina Saimanen; Viivi Kuosmanen; Jukka Harju; Tuomas Selander; Samuli Aspinen; Matti Eskelinen Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Kathryn M Greven; L Douglas Case; Lawrence R Nycum; Patricia J Zekan; David D Hurd; Ernie P Balcueva; Glenn M Mills; Robin Zon; Patrick J Flynn; David Biggs; Edward G Shaw; Glenn Lesser; Michelle J Naughton Journal: J Community Support Oncol Date: 2015-03
Authors: Maria Ida Maiorino; Paolo Chiodini; Giuseppe Bellastella; Dario Giugliano; Katherine Esposito Journal: Endocrine Date: 2015-12-07 Impact factor: 3.633
Authors: Shannon Myers Virtue; Sharon L Manne; Melissa Ozga; David W Kissane; Stephen Rubin; Carolyn Heckman; Norm Rosenblum; John J Graff Journal: Int J Gynecol Cancer Date: 2014-01 Impact factor: 3.437
Authors: Georgina L Jones; Richard M Jacques; Joanne Thompson; Hilary J Wood; Jane Hughes; William Ledger; Mo'iad Alazzam; Stephen C Radley; John A Tidy Journal: Psychooncology Date: 2015-09-25 Impact factor: 3.894